Table 4.
Estimation of the difference in the enzyme activities between the intervention groups evaluated at week 4 of the study.
| Variable | Enriched Yogurt vs. Control | Plain Yogurt vs. Control | Enriched vs. Plain Yogurt |
|---|---|---|---|
| PAF-AH (pmol/mg/min) | −3.90 (−8.47, 0.66) | −9.88 (−23.05, 3.28) | 2.59 (−10.83, 16.01) |
| LpPLA2 (nmol/mL/min) | −0.43 (−1.14, 0.28) | −0.28 (−1.82, 1.25) | −0.65 (−2.48, 1.18) |
| PAF-CPT (pmol/mg/min) | −6.48 (−12.04, −0.92) | −16.36 (−33.82, 1.11) | 5.14 (−6.91, 17.19) |
| Lyso-PAF ATC (pmol/mg/min) | −0.96 (−13.38, 11.45) | −11.81 (−30.11, 6.49) | −11.16 (−31.07, 8.75) |
| Lyso-PAF ATE (pmol/mg/min) | −0.22 (−3.23, 2.78) | −2.28 (−8.92, 4.36) | 3.24 (−4.82, 11.30) |
| LpPLA2-to-LDL ratio | −0.003 (−0.009, 0.004) | −0.001 (−0.015, 0.013) | −0.005 (−0.012, 0.003) |
Median regression was performed for each pair of intervention groups; adjustments were made for sex and enzyme variable values at baseline. Results are presented as difference in medians (95% confidence interval of the difference) between intervention groups. Significance (α) level was set to 0.05. BMI: body mass index; LDL: low-density lipoprotein; LpPLA2: lipoprotein-associated phospholipase A2; Lyso-PAF ATC: lyso-platelet-activating factor acetyltransferase in the presence of Ca2+; Lyso-PAF ATE: lyso-platelet-activating factor acetyltransferase in the presence of EDTA; PAF-AH: platelet-activating acetyl-hydrolase; PAF-CPT: platelet-activating factor-cholinephosphotransferase.